Pennsylvania Wegovy Side Effects Lawyer

DIABETES AND WEIGHT LOSS DRUG STOMACH PARALYSIS CLAIMS IN PENNSYLVANIA

If you’ve been prescribed Wegovy for weight management in Pennsylvania, home to approximately 12.8 million residents, and are now facing adverse reactions, be assured you’re not alone. Several Pennsylvanians among our vast population have come forward with complications after administering Wegovy (semaglutide). As you weigh the option of filing a Wegovy-related claim here in Pennsylvania, our seasoned team of pharmaceutical liability lawyers stands prepared to guide you. Choosing an adept Wegovy complications attorney is essential. Contact us and we’ll find the best lawyer for your needs.

Wegovy, containing the active ingredient semaglutide, has FDA approval as an injectable medication primarily prescribed for weight control. It functions by imitating a hormone that targets specific brain areas to regulate appetite. As part of the glucagon-like peptide-1 (GLP-1) receptor agonists category, this medication has also found use in diabetes treatments.

The prominence of semaglutide for weight loss has garnered significant attention. Drugs such as Wegovy, Ozempic, Rybelsus, Trulicity, Mounjaro, and Saxenda, originally developed for diabetics, are now being heralded as revolutionary weight loss agents. Though designed for the obese, it’s alarming that many without obesity are opting for it, hoping for additional weight loss benefits. However, like many drugs, potential risks abound. The surge in reported side effects has naturally led to an increase in Wegovy-related lawsuits, not just nationally but also within Pennsylvania.

The creator of Wegovy, Novo Nordisk, is headquartered in Denmark. If you are a current resident of Pennsylvanian and have suffered from adverse effects after taking semaglutide, it might be time to explore legal recourse against Novo Nordisk. Such actions might involve a product liability lawsuit, encompassing grounds of negligence, failure to adequately warn of risks, manufacturing defects, or other relevant legal bases aligned with Pennsylvania statutes. For those severely affected post-Wegovy usage and are contemplating taking action against the manufacturer, fill out the free case evaluation form below to see if you have a case:

INDIVIDUAL CLAIM VERSUS CLASS ACTION IN PENNSYLVANIA: WHICH TO CHOOSE?

While the idea of participating in a Wegovy class action may arise, it’s often recommended, particularly with severe side effects, to pursue an individual claim under Pennsylvania law. This route might accelerate the resolution process and potentially secure a more substantial compensation package.

POTENTIAL SIDE EFFECTS OF WEGOVY: WHAT PENNSYLVANIANS SHOULD KNOW

Should you experience persistent digestive issues like nausea, vomiting, bloating, or abdominal pain while on Wegovy, it’s crucial to seek medical counsel for potential stomach paralysis or slow stomach emptying. The FDA has been alerted to several serious health concerns. Highlighted below are the most concerning potential side effects of Wegovy (semaglutide):

• Gastroparesis: Often referred to as stomach paralysis, this condition impairs the stomach’s efficient emptying.
• Pancreatitis: It signifies an inflamed pancreas and, although rare, is serious. Symptoms encompass sharp abdominal pain, nausea, and vomiting. Immediate medical intervention is crucial.
• Gallbladder Concerns: Consumption of Wegovy may elevate the risk of gallstones or inflammation of the gallbladder. Warning signs include severe abdominal discomfort, fever, and a yellowish skin hue.
• Renal Complications: Semaglutide has occasionally been associated with renal impairment. Symptoms might include nausea, vomiting, loss of appetite, and compromised renal function.
• Hypoglycemia: For diabetics on concurrent insulin or other glucose-lowering medications, Wegovy poses a risk of severely low blood sugar, evident through confusion, excessive sweating, or an accelerated heartbeat.
• Allergic Reactions: Some might suffer intense allergic responses to semaglutide, with manifestations like rashes, edema, or breathing issues.
• Thyroid Tumors: GLP-1 receptor agonists, including Wegovy, have been linked to an increased likelihood of thyroid C-cell tumors, including medullary thyroid carcinoma.
• Exacerbation of Diabetic Retinopathy: Wegovy can, in certain instances, aggravate existing diabetic eye complications.
• Vision Issues: A subset of users may report vision changes or encounter eye-related concerns, especially if they have a history of diabetic retinopathy.

For all Pennsylvania residents affected or with concerns about Wegovy, our legal team is here to help you through this complicated situation. Reach out to us today for a free case review.

Hospitals throughout Pennsylvania: